Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer
Abstract In a previous study, we detected a significant association between phosphoserine aminotransferase 1 (PSAT1) hyper-methylation and mRNA levels to outcome to tamoxifen treatment in recurrent disease. We here aimed to study the association of PSAT1 protein levels to outcome upon tamoxifen trea...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/dbc96afce5a543d8b843426a5e4e8e64 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:dbc96afce5a543d8b843426a5e4e8e64 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:dbc96afce5a543d8b843426a5e4e8e642021-12-02T11:53:05ZPhosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer10.1038/s41598-017-02296-w2045-2322https://doaj.org/article/dbc96afce5a543d8b843426a5e4e8e642017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02296-whttps://doaj.org/toc/2045-2322Abstract In a previous study, we detected a significant association between phosphoserine aminotransferase 1 (PSAT1) hyper-methylation and mRNA levels to outcome to tamoxifen treatment in recurrent disease. We here aimed to study the association of PSAT1 protein levels to outcome upon tamoxifen treatment and to obtain more insight in its role in tamoxifen resistance. A cohort of ER positive, hormonal therapy naïve primary breast carcinomas was immunohistochemically (IHC) stained for PSAT1. Staining was analyzed for association with patient’s time to progression (TTP) and overall response on first-line tamoxifen for recurrent disease. PSAT1 mRNA levels were also assessed by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR; n = 161) and Affymetrix GeneChip (n = 155). Association of PSAT1 to biological pathways on tamoxifen outcome were assessed by global test. PSAT1 protein and mRNA levels were significantly associated to poor outcome to tamoxifen treatment. When comparing PSAT1 protein and mRNA levels, IHC and RT-qPCR data showed a significant association. Global test results showed that cytokine and JAK-STAT signaling were associated to PSAT1 expression. We hereby report that PSAT1 protein and mRNA levels measured in ER positive primary tumors are associated with poor clinical outcome to tamoxifen.Tommaso De MarchiMieke A. TimmermansAnieta M. SieuwertsMarcel SmidMaxime P. LookNicolai GrebenchtchikovFred C. G. J. SweepJan G. SmitsViktor MagdolenCarolien H. M. van DeurzenJohn A. FoekensArzu UmarJohn W. MartensNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-11 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Tommaso De Marchi Mieke A. Timmermans Anieta M. Sieuwerts Marcel Smid Maxime P. Look Nicolai Grebenchtchikov Fred C. G. J. Sweep Jan G. Smits Viktor Magdolen Carolien H. M. van Deurzen John A. Foekens Arzu Umar John W. Martens Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer |
| description |
Abstract In a previous study, we detected a significant association between phosphoserine aminotransferase 1 (PSAT1) hyper-methylation and mRNA levels to outcome to tamoxifen treatment in recurrent disease. We here aimed to study the association of PSAT1 protein levels to outcome upon tamoxifen treatment and to obtain more insight in its role in tamoxifen resistance. A cohort of ER positive, hormonal therapy naïve primary breast carcinomas was immunohistochemically (IHC) stained for PSAT1. Staining was analyzed for association with patient’s time to progression (TTP) and overall response on first-line tamoxifen for recurrent disease. PSAT1 mRNA levels were also assessed by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR; n = 161) and Affymetrix GeneChip (n = 155). Association of PSAT1 to biological pathways on tamoxifen outcome were assessed by global test. PSAT1 protein and mRNA levels were significantly associated to poor outcome to tamoxifen treatment. When comparing PSAT1 protein and mRNA levels, IHC and RT-qPCR data showed a significant association. Global test results showed that cytokine and JAK-STAT signaling were associated to PSAT1 expression. We hereby report that PSAT1 protein and mRNA levels measured in ER positive primary tumors are associated with poor clinical outcome to tamoxifen. |
| format |
article |
| author |
Tommaso De Marchi Mieke A. Timmermans Anieta M. Sieuwerts Marcel Smid Maxime P. Look Nicolai Grebenchtchikov Fred C. G. J. Sweep Jan G. Smits Viktor Magdolen Carolien H. M. van Deurzen John A. Foekens Arzu Umar John W. Martens |
| author_facet |
Tommaso De Marchi Mieke A. Timmermans Anieta M. Sieuwerts Marcel Smid Maxime P. Look Nicolai Grebenchtchikov Fred C. G. J. Sweep Jan G. Smits Viktor Magdolen Carolien H. M. van Deurzen John A. Foekens Arzu Umar John W. Martens |
| author_sort |
Tommaso De Marchi |
| title |
Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer |
| title_short |
Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer |
| title_full |
Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer |
| title_fullStr |
Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer |
| title_full_unstemmed |
Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer |
| title_sort |
phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/dbc96afce5a543d8b843426a5e4e8e64 |
| work_keys_str_mv |
AT tommasodemarchi phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer AT miekeatimmermans phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer AT anietamsieuwerts phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer AT marcelsmid phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer AT maximeplook phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer AT nicolaigrebenchtchikov phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer AT fredcgjsweep phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer AT jangsmits phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer AT viktormagdolen phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer AT carolienhmvandeurzen phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer AT johnafoekens phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer AT arzuumar phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer AT johnwmartens phosphoserineaminotransferase1isassociatedtopooroutcomeontamoxifentherapyinrecurrentbreastcancer |
| _version_ |
1718394898400411648 |